ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 0700

Distinct Breath Metabolomic Signature in Systemic Sclerosis Patients with Pulmonary Arterial Hypertension
Abstract Number: 0701

Exploring Calcinosis On Hand X-Rays In Systemic Sclerosis: a Mayo Clinic Cohort
Abstract Number: 0702

Effectiveness of Oral Anticoagulants in Precapillary Pulmonary Hypertension Associated with Systemic Sclerosis: a EUSTAR Cohort Study.
Abstract Number: 0703

Trends and Disparities in Systemic Sclerosis-related Mortality Rates in the United States from 1999 to 2023
Abstract Number: 0704

Human Pharmacokinetics of Inhaled Liposomal Iloprost Support a Dosing Regimen for Treating Systemic Sclerosis- Related Digital Ulcer
Abstract Number: 0705

Multimodal Imaging Evaluation of Patients with Raynaud’s Phenomenon meeting the Criteria for “Early” Systemic Sclerosis according to LeRoy versus Healthy Controls: a Prospective Cross-sectional study
Abstract Number: 0706

Major salivary glands Ultrasound features in a group of patients with systemic sclerosis: a multicentric study
Abstract Number: 0707

When Can Support Lead to Missed Clinic Appointments in Patients with Systemic Lupus Erythematosus?
Abstract Number: 0708

Association Of Choroidal Sub-foveal Thickness With Skin Manifestations And Serum Monocyte HDL Ratio In Patients With Systemic Sclerosis-A Case Control Study
Abstract Number: 0709

Systemic Sclerosis Inducible Pluripotential Stem Cells Reprogrammed into Endothelial Cells Identify Vascular Permeability May Not Be Cytokine Driven
Abstract Number: 0710

Vascular Events in Systemic Sclerosis Patients with Anti-Phospholipid Antibodies
Abstract Number: 0711

Analytical Performance of a Novel, Fully Automated Multiplexed Microarray Immunoassay Prototype for the Simultaneous Detection of Autoantibodies to GBM, PR3, and MPO: A Multicenter Evaluation
Abstract Number: 0712

Effects of Bacterial Secretome on Nasal Epithelial Cell Gene Expression in ANCA-Associated Vasculitis
Abstract Number: 0713

Differentiating Primary Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis from Secondary Forms
Abstract Number: 0714

Factors Associated With Depression And Anxiety In ANCA-Associated Vasculitis Patients: Data From The Almenara Vasculitis Cohort

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].